RDPTF (Radiopharm Theranostics) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Debt-to-Equity?

Radiopharm Theranostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Radiopharm Theranostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Radiopharm Theranostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $16.22 Mil. Radiopharm Theranostics's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Radiopharm Theranostics's Debt-to-Equity or its related term are showing as below:

RDPTF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Radiopharm Theranostics Debt-to-Equity Historical Data

The historical data trend for Radiopharm Theranostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Debt-to-Equity Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Jun24

Debt-to-Equity

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Radiopharm Theranostics's Debt-to-Equity

For the Biotechnology subindustry, Radiopharm Theranostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Debt-to-Equity falls into.

Radiopharm Theranostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Radiopharm Theranostics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	18.674
	=	0.00

Radiopharm Theranostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	16.221
	=	0.00

Radiopharm Theranostics (OTCPK:RDPTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Radiopharm Theranostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics Headlines

From GuruFocus

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022